Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04115072

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

Sponsor: Charite University, Berlin, Germany

Interventions Praziquantel 600Mg Oral Tablet x 1 Praziquantel 600Mg Oral Tablet x 5

Updated 7 times since 2019 Last updated: May 15, 2020 Started: Sep 3, 2019 Primary completion: Feb 21, 2020 Completion: Feb 21, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04115072, this PHASE2/PHASE3 trial focuses on Schistosomiasis and remains completed. Sponsored by Charite University, Berlin, Germany, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Nov 2024 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Feb 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Nov 2019 — Feb 2020 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charite University, Berlin, Germany
Leiden University Medical Center
Merck Serono International SA
Ministry of Health, Madagascar
Nagasaki University
Regionshospital Nordjylland
Umeå University

Data source: Regionshospital Nordjylland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ambanja, Madagascar